Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2014

Open Access 01-12-2014 | Research

Decreased expression of eukaryotic initiation factor 3f is an adverse prognostic factor for stage I–III gastric cancer

Authors: Guanghua Li, Na Wang, Chuanjin Sun, Bo Li

Published in: World Journal of Surgical Oncology | Issue 1/2014

Login to get access

Abstract

Background

It has been demonstrated that eIF3f expression is significantly decreased in many human cancers, a fact which plays an important role in human cancer. However, the expression of eIF3f in gastric cancer (GC) is not well understood to date. Therefore, the aim of this study is to detect the expression of eIF3f in GC.

Methods

The expression of eIF3f was examined by immunohistochemistry in tissues with stage I to III GC and adjacent non-cancerous tissues (ANCT) of 195 gastrectomy specimens; clinicopathological results, including survival, were analyzed.

Results

The positive expression rate of eIF3f was significantly higher in ANCT tissues than in GC. eIF3f levels were correlated with more advanced tumor stages and likelihood of recurrence (all P <0.05). The Kaplan-Meier survival curves indicated that decreased expression of eIF3f could serve as a prognosis marker for poor outcome of GC patients (P = 0.04).

Conclusions

eIF3f may play an important role in recurrence, thus representing a promising predictive marker for the prognosis of GC.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2013, 61: 69-90.CrossRef
2.
Batista TP, Santos CA, Almeida GF: Perioperative chemotherapy in locally advanced gastric cancer. Arq Gastroenterol. 2013, 50: 236-242. 10.1590/S0004-28032013000200042.CrossRefPubMed
3.
Xiao JW, Chen JH, Ren MY, Tian XB, Wang CS: Relationship between expression of gastrokine 1 and clinicopathological characteristics in gastric cancer patients. Asian Pac J Cancer Prev. 2012, 13: 5897-5901. 10.7314/APJCP.2012.13.11.5897.CrossRefPubMed
4.
5.
Juca PC, Lourenco L, Kesley R, Mello EL, Oliveira IM, Correa JH: Comparison of survival and prognostic factors in patients with gastric adenocarcinoma in T2 and T3. Rev Col Bras Cir. 2012, 39 (5): 377-384. 10.1590/S0100-69912012000500007.CrossRefPubMed
6.
Xing X, Tang Y, Yuan G, Wang Y, Wang J, Yang Y, Chen M: The prognostic value of E-cadherin in gastric cancer: a meta-analysis. Int J Cancer. 2013, 132 (11): 2589-2596. 10.1002/ijc.27947.CrossRefPubMed
7.
Hu BS, Hu H, Zhu CY, Gu YL, Li JP: Overexpression of GOLPH3 is associated with poor clinical outcome in gastric cancer. Tumour Biol: J Int Soc Oncodev Biol Med. 2013, 34 (1): 515-520.CrossRef
8.
Pan XF, Xie Y, Loh M, Yang SJ, Wen YY, Tian Z, Huang H, Lan H, Chen F, Soong R, Yang CX: Polymorphisms of XRCC1 and ADPRT genes and risk of noncardia gastric cancer in a Chinese population: a case-control study. Asian Pac J Cancer Prev. 2012, 13 (11): 5637-5642. 10.7314/APJCP.2012.13.11.5637.CrossRefPubMed
9.
Xiao H, Xu LH, Yamada Y, Liu DX: Coronavirus spike protein inhibits host cell translation by interaction with eIF3f. PLoS One. 2008, 3 (1): e1494-10.1371/journal.pone.0001494.PubMedCentralCrossRefPubMed
10.
Masutani M, Sonenberg N, Yokoyama S, Imataka H: Reconstitution reveals the functional core of mammalian eIF3. EMBO J. 2007, 26 (14): 3373-3383. 10.1038/sj.emboj.7601765.PubMedCentralCrossRefPubMed
11.
Shi J, Kahle A, Hershey JW, Honchak BM, Warneke JA, Leong SP, Nelson MA: Decreased expression of eukaryotic initiation factor 3f deregulates translation and apoptosis in tumor cells. Oncogene. 2006, 25 (35): 4923-4936. 10.1038/sj.onc.1209495.CrossRefPubMed
12.
Wen F, Zhou R, Shen A, Choi A, Uribe D, Shi J: The tumor suppressive role of eIF3f and its function in translation inhibition and rRNA degradation. PLoS One. 2012, 7 (3): e34194-10.1371/journal.pone.0034194.PubMedCentralCrossRefPubMed
13.
Moretti J, Chastagner P, Gastaldello S, Heuss SF, Dirac AM, Bernards R, Masucci MG, Israel A, Brou C: The translation initiation factor 3f (eIF3f) exhibits a deubiquitinase activity regulating Notch activation. PLoS Biol. 2010, 8 (11): e1000545-10.1371/journal.pbio.1000545.PubMedCentralCrossRefPubMed
14.
Jiang B, Zhang B, Liang P, Song J, Deng H, Tu Z, Deng G, Xiao X: Nucleolin/C23 mediates the antiapoptotic effect of heat shock protein 70 during oxidative stress. FEBS J. 2010, 277 (3): 642-652. 10.1111/j.1742-4658.2009.07510.x.CrossRefPubMed
15.
Ray A, Bandyopadhyay A, Matsumoto T, Deng H, Maitra U: Fission yeast translation initiation factor 3 subunit eIF3h is not essential for global translation initiation, but deletion of eif3h + affects spore formation. Yeast. 2008, 25 (11): 809-823. 10.1002/yea.1635.CrossRefPubMed
16.
Doldan A, Chandramouli A, Shanas R, Bhattacharyya A, Leong SP, Nelson MA, Shi J: Loss of the eukaryotic initiation factor 3f in melanoma. Mol Carcinog. 2008, 47 (10): 806-813. 10.1002/mc.20436.PubMedCentralCrossRefPubMed
17.
Marchione R, Leibovitch SA, Lenormand JL: The translational factor eIF3f: the ambivalent eIF3 subunit. Cell Mol Life Sci. 2013, 70: 3603-3616. 10.1007/s00018-013-1263-y.PubMedCentralCrossRefPubMed
18.
Shi J, Hershey JW, Nelson MA: Phosphorylation of the eukaryotic initiation factor 3f by cyclin-dependent kinase 11 during apoptosis. FEBS Lett. 2009, 583 (6): 971-977. 10.1016/j.febslet.2009.02.028.PubMedCentralCrossRefPubMed
19.
Doldan A, Chandramouli A, Shanas R, Bhattacharyya A, Cunningham JT, Nelson MA, Shi J: Loss of the eukaryotic initiation factor 3f in pancreatic cancer. Mol Carcinog. 2008, 47 (3): 235-244. 10.1002/mc.20379.PubMedCentralCrossRefPubMed
20.
Higareda-Mendoza AE, Pardo-Galvan MA: Expression of human eukaryotic initiation factor 3f oscillates with cell cycle in A549 cells and is essential for cell viability. Cell Division. 2010, 5: 10-10.1186/1747-1028-5-10.PubMedCentralCrossRefPubMed
21.
22.
Hadi R, Mohanti BK, Pathy S, Rath GK, Shukla NK, Deo SV, Sharma A, Raina V: Gastric cancer: a retrospective analysis from AIIMS, New Delhi. Gulf J Oncolog. 2012, 1 (12): 11-16.
23.
Zagouri F, Papadimitriou CA, Dimopoulos MA, Pectasides D: Molecularly targeted therapies in unresectable-metastatic gastric cancer: a systematic review. Cancer Treat Rev. 2011, 37 (8): 599-610. 10.1016/j.ctrv.2011.03.007.CrossRefPubMed
24.
Fujitani K, Yamada M, Hirao M, Kurokawa Y, Tsujinaka T: Optimal indications of surgical palliation for incurable advanced gastric cancer presenting with malignant gastrointestinal obstruction. Gastric Cancer. 2011, 14 (4): 353-359. 10.1007/s10120-011-0053-1.CrossRefPubMed
25.
D’Ugo D, Persiani R, Zoccali M, Cananzi F, Vigorita V, Mazzeo P, Tufo A, Biondi A: Surgical issues after neoadjuvant treatment for gastric cancer. Eur Rev Med Pharmacol Sci. 2010, 14 (4): 315-319.PubMed
26.
Valente ST, Gilmartin GM, Mott C, Falkard B, Goff SP: Inhibition of HIV-1 replication by eIF3f. Proc Natl Acad Sci USA. 2009, 106 (11): 4071-4078. 10.1073/pnas.0900557106.PubMedCentralCrossRefPubMed
Metadata
Title
Decreased expression of eukaryotic initiation factor 3f is an adverse prognostic factor for stage I–III gastric cancer
Authors
Guanghua Li
Na Wang
Chuanjin Sun
Bo Li
Publication date
01-12-2014
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2014
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-12-72

Other articles of this Issue 1/2014

World Journal of Surgical Oncology 1/2014 Go to the issue

Research

Latexin inhibits the proliferation of CD133+ miapaca-2 pancreatic cancer stem-like cells

Research

Comparison of laparoscopic peritoneal vaginoplasty and sigmoid colon vaginoplasty performed during radical surgery for primary vaginal carcinoma

Technical innovations

Magnetic resonance imaging-guided occult breast lesion localization and simultaneous sentinel lymph node mapping

Research

Modified liver mobilization for the treatment of renal cell carcinoma with thrombosis involving the intrahepatic inferior vena cava

Research

Pharyngoesophageal reconstruction after resection of hypopharyngeal carcinoma: a new algorithm after analysis of 142 cases

Research

Predictors of recurrence after a first hepatectomy for colorectal cancer liver metastases: a retrospective analysis